Trial · NCT03355300
Adverse events22
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 22
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vomiting | Gastrointestinal disorders | Canabidiol Oral Solution 20 to <30 mg/kg/Day | 0 | 5 | |
| other | Vomiting | Gastrointestinal disorders | Canabidiol Oral Solution 30 to <40 mg/kg/Day | 1 | 6 | |
| other | Fatigue | General disorders | Canabidiol Oral Solution 20 to <30 mg/kg/Day | 0 | 5 | |
| other | Fatigue | General disorders | Canabidiol Oral Solution 30 to <40 mg/kg/Day | 1 | 6 | |
| other | Pyrexia | General disorders | Canabidiol Oral Solution 20 to <30 mg/kg/Day | 1 | 5 | |
| other | Pyrexia | General disorders | Canabidiol Oral Solution 30 to <40 mg/kg/Day | 0 | 6 | |
| other | Seasonal allergy | Immune system disorders | Canabidiol Oral Solution 20 to <30 mg/kg/Day | 1 | 5 | |
| other | Seasonal allergy | Immune system disorders | Canabidiol Oral Solution 30 to <40 mg/kg/Day | 0 | 6 | |
| other | Pharyngitis streptococcal | Infections and infestations | Canabidiol Oral Solution 20 to <30 mg/kg/Day | 0 | 5 | |
| other | Pharyngitis streptococcal | Infections and infestations | Canabidiol Oral Solution 30 to <40 mg/kg/Day | 1 | 6 | |
| other | Upper respiratory tract infection | Infections and infestations | Canabidiol Oral Solution 20 to <30 mg/kg/Day | 0 | 5 | |
| other | Upper respiratory tract infection | Infections and infestations | Canabidiol Oral Solution 30 to <40 mg/kg/Day | 1 | 6 | |
| other | Coordination abnormal | Nervous system disorders | Canabidiol Oral Solution 20 to <30 mg/kg/Day | 1 | 5 | |
| other | Coordination abnormal | Nervous system disorders | Canabidiol Oral Solution 30 to <40 mg/kg/Day | 0 | 6 | |
| other | Headache | Nervous system disorders | Canabidiol Oral Solution 20 to <30 mg/kg/Day | 1 | 5 | |
| other | Headache | Nervous system disorders | Canabidiol Oral Solution 30 to <40 mg/kg/Day | 0 | 6 | |
| other | Seizure | Nervous system disorders | Canabidiol Oral Solution 20 to <30 mg/kg/Day | 1 | 5 | |
| other | Seizure | Nervous system disorders | Canabidiol Oral Solution 30 to <40 mg/kg/Day | 0 | 6 | |
| other | Somnolence | Nervous system disorders | Canabidiol Oral Solution 20 to <30 mg/kg/Day | 1 | 5 | |
| other | Somnolence | Nervous system disorders | Canabidiol Oral Solution 30 to <40 mg/kg/Day | 0 | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03355300/events